UraniaRappoMD

Infectious Disease • New York, NY

Physician

Join to view full profile

Dr. Rappo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rappo's full profile

Already have an account?

Office
550 1st Ave
New York, NY 10016
Phone+1 212-686-7500

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Infectious Disease, 2009 - 2011
NYU Grossman School of MedicineResidency, Internal Medicine, 2006 - 2009
Drexel University College of MedicineClass of 2006

Certifications & Licensure

NY State Medical License 2009 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis Start of enrollment: 2016 Mar 15
Completed
Phase 2
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis Start of enrollment: 2017 May 12
Terminated
Phase 2

Publications & Presentations

PubMed

2 citations
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical...
Todd Riccobene, John Lock, Rosie D Lyles, Benjamin Georgiades, Michael Nowak
Open Forum Infectious Diseases. 2023-06-01
207 citations
Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation.
Sara Federici, Sharon Kredo-Russo, Rafael Valdés-Mas, Denise Kviatcovsky, Eyal Weinstock
Cell. 2022-08-04
22 citations
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Nicholas A Turner, Smitha Zaharoff, Heather King, Scott Evans, Toshimitsu Hamasaki
Trials. 2022-05-16

Press Mentions

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis ConferenceSeptember 18th, 2024